Read + Share
Eadie LN, Lagonik E, Page EC, Schutz CE, et al. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires
the ABL SH3 domain for efficacy. Blood 2024;144:1022-1026.
PMID: 38848536
|
 |
|
Eadie LN, Lagonik E, Page EC, Schutz CE, et al. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires
the ABL SH3 domain for efficacy. Blood 2024;144:1022-1026.
PMID: 38848536
|
|
|
|